Big Pharma is abusing patents, and it's hurting Americans

12 September 2019 - The American patent system has, since our nation's founding, served as a cornerstone of innovation. But ...

Read more →

Subscription model for antibiotic development

6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...

Read more →

Gilead files challenge to government patents for HIV prevention pill

21 August 2019 - Gilead Sciences took the unusual step of mounting a challenge to U.S. government patents on Wednesday, ...

Read more →

Chinese stealing health and medical research data: report

21 August 2019 - The global healthcare sector, including Australia, faces increasing cyber threats and malicious activity from Chinese groups, ...

Read more →

Is ‘competitive licensing’ proposed in HR 1046 practical for lowering drug prices?

29 July 2019 - The pricing of prescription drugs is a source of current public consternation in the US.  ...

Read more →

Intellectual property law amends will add to business uncertainty

26 July 2019 - Medicines Australia supports efforts to strengthen Australia’s Intellectual Property arrangements to be consistent with international best ...

Read more →

How pharma, under attack from all sides, keeps winning in Washington

16 July 2019 - It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy ...

Read more →

With eyes on Gilead, law makers want details on how HHS reviews possible patent infringement

18 June 2019 - A pair of law makers has asked the Government Accountability Office to review how the U.S. ...

Read more →

They were supposed to talk about the patent system driving up drug prices. But most lawmakers got distracted by small tweaks.

7 May 2019 - If there was any hope that Congress might overhaul the way this country doles out the ...

Read more →

Pharmaceutical protections in U.S. trade deals — what do Americans get in return?

1 May 2019 - U.S. trade deals increasingly include terms affecting the approval process and availability of medicines.  ...

Read more →

Drug company protections are latest stumbling block for NAFTA rewrite

21 March 2019 - President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge ...

Read more →

‘One-and-done’ for new drugs could cut patent thickets and boost generic competition

11 February 2019 - In a perfect world, the system for conveying medications from their makers to patients should be ...

Read more →

Patent abuse is driving up drug prices. Just look at Lantus.

7 December 2018 -  A rare point of consensus following the midterm elections is that Americans are adamant about lowering ...

Read more →

AbbVie announces Humira (adalimumab) global patent license with Pfizer

30 November 2018 - AbbVie announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product.  ...

Read more →

AbbVie announces Humira (adalimumab) global patent license with Momenta

6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.  ...

Read more →